REGENERON PHARMACEUTICALS, INC. Annual Report (Amendment), Year Ended Dec 31, 2009

Regeneron Pharmaceuticals, Inc. (REGN) filed an amendment to its 2009 Annual Report (10-K/A) on June 1, 2010. This filing primarily provides access to the company's exhibits and financial statement schedules. For investors, the most critical information would be found in the detailed financial statements themselves, which are typically included or referenced in the 10-K, and the exhibits which may contain material agreements, contracts, and other documents that provide deeper insight into the company's operations, strategic partnerships, and potential liabilities or opportunities. While this specific amendment focuses on the supplementary sections, a thorough investor analysis would require reviewing the complete 10-K filing for the period ending December 30, 2009. This would include management's discussion and analysis of financial condition and results of operations, risk factors, and details on the company's product pipeline and development stage. Investors should look for information regarding revenue generation, research and development expenditures, clinical trial progress, and any significant collaborations or licensing agreements that could impact future growth.